Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16175358 | 0.94 | SCN9A (0.54) | SCN9ASCN5A | |
| SCHEMBL15544113 | 0.91 | SCN9A (0.51) | SCN9ASCN5A | |
| SCHEMBL1690160 | 0.91 | SCN9A (0.69) | SCN9ASCN5A | |
| SCHEMBL17244933 | 0.90 | SCN9A (0.58) | SCN9ASCN5A | |
| SCHEMBL15599208 | 0.89 | SCN9A (0.64) | SCN9ASCN5A | |
| SCHEMBL15543933 | 0.88 | SCN9A (0.65) | SCN9ASCN5A | |
| SCHEMBL15558876 | 0.87 | SCN9A (0.72) | SCN9ASCN5A | |
| SCHEMBL15542946 | 0.86 | SCN9A (0.65) | SCN9ASCN5A | |
| SCHEMBL19411921 | 0.85 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL16175064 | 0.85 | SCN9A (0.57) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-2870138-B1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2014008458-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322002-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, SNRPD2, RDX | SCN9A 1104/4885SCN5A 724/4885 |
| US-10071957-B2 | N-substituted benzamides and methods of use thereof | BRIX1, SNRPD2, RDX | SCN9A 1104/4885SCN5A 724/4885 |
| US-20180346416-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, P2RX3 | SCN9A 501/4885SCN5A 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.